Beta Amyloid News and Research RSS Feed - Beta Amyloid News and Research

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries. [More]
EMA CHMP recommends marketing authorization for GE's VIZAMYL for PET imaging to detect beta amyloids

EMA CHMP recommends marketing authorization for GE's VIZAMYL for PET imaging to detect beta amyloids

GE Healthcare today announced the receipt of a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use. This opinion recommends the granting of a marketing authorisation for VIZAMYL (Flutemetamol F18 injection), a radiopharmaceutical medicinal product indicated for Positron Emission Tomography imaging of beta amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive impairment. [More]
Late-life depression could become major risk factor for developing Alzheimer's

Late-life depression could become major risk factor for developing Alzheimer's

Many people develop depression in the latest stages of life, but until now doctors had no idea that it could point to a build up of a naturally occurring protein in the brain called beta-amyloid, a hallmark of Alzheimer's disease. [More]
GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare announces commercial availability of new Alzheimer’s diagnostic tool

GE Healthcare today announced the first seven markets where Vizamyl (Flutemetamol F18 injection), a radioactive diagnostic agent approved by the FDA will be available. Late in the second quarter of 2014, Vizamyl will be available to imaging centers near East Rutherford, NJ, Woburn, MA, Beltsville, MD, East Lansing, MI, Dallas, TX, Phoenix, AZ and Colton, CA. [More]
NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

NeuroPhage engineers series of molecules with potential to treat most neurodegenerative diseases

​Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. [More]
Research sheds new light onto possible causes of sudden infant death syndrome

Research sheds new light onto possible causes of sudden infant death syndrome

Research at the University of Adelaide has shed new light onto the possible causes of sudden infant death syndrome (SIDS), which could help to prevent future loss of children's lives. [More]
Researchers identify eight new active molecules against Alzheimer

Researchers identify eight new active molecules against Alzheimer

Researchers of the Unit of Medicine Design and Molecular Topology (Department of Physics Chemistry) of the University of Valencia have discovered eight new active molecules against Alzheimer by a novel mechanism of action, different to the currently used medicines. The work has just been published in the "Plos One" magazine. [More]
New lab at the Nencki Institute conducts research on neurodegenerative diseases

New lab at the Nencki Institute conducts research on neurodegenerative diseases

The Laboratory of Preclinical Studies of Higher Standard, the newest lab of the Neurobiology Center at the Nencki Institute in Warsaw, Poland, will conduct basic research aimed to explain molecular mechanisms responsible for neurodegenerative diseases. [More]
Caffeine has positive effect on tau deposits in Alzheimer's disease

Caffeine has positive effect on tau deposits in Alzheimer's disease

As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease. [More]
Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology releases top-line results of PBT2 Phase II Imaging trial in Alzheimer's disease

Prana Biotechnology has today released the top line results of the 12-month Phase II Imaging trial in Alzheimer's Disease ("IMAGINE" Trial), based on draft results. [More]
Plaque in brain could guide treatment decisions for patients at risk for Alzheimer's

Plaque in brain could guide treatment decisions for patients at risk for Alzheimer's

Brain imaging using radioactive dye can detect early evidence of Alzheimer's disease that may predict future cognitive decline among adults with mild or no cognitive impairment, according to a 36-month follow-up study led by Duke Medicine. [More]
Researchers examine impact of diet for preventing Alzheimer's dementia

Researchers examine impact of diet for preventing Alzheimer's dementia

A cocktail of ingredients containing omega-3 fatty acid found in fish oil is being tested in patients with mild cognitive impairment as a means to slow the progression of Alzheimer's dementia down [More]
ACE protein overexpression elevates immune responses and prevents Alzheimer's-like cognitive decline

ACE protein overexpression elevates immune responses and prevents Alzheimer's-like cognitive decline

Many people with high blood pressure are familiar with ACE inhibitors, drugs that widen blood vessels by limiting activity of ACE - angiotensin-converting enzyme - a naturally occurring protein found in tissues throughout the body. [More]
Presence of gene variant in people with MCI associated with accelerated rates of brain atrophy

Presence of gene variant in people with MCI associated with accelerated rates of brain atrophy

The presence of a gene variant in people with mild cognitive impairment is associated with accelerated rates of brain atrophy, according to a new study published online in the journal Radiology. [More]
Study: Brain blood vessel cells may be therapeutic targets for Alzheimer's disease

Study: Brain blood vessel cells may be therapeutic targets for Alzheimer's disease

A study in mice shows how a breakdown of the brain's blood vessels may amplify or cause problems associated with Alzheimer's disease. The results published in Nature Communications suggest that blood vessel cells called pericytes may provide novel targets for treatments and diagnoses. [More]
Spaceflights cause cellular-level damage and may lead to long-term vision problems

Spaceflights cause cellular-level damage and may lead to long-term vision problems

Those who travel to space are rewarded with a beautiful sight - planet Earth. But the effects of space travel on the human sense of sight aren't so beautiful. More than 30 percent of astronauts who returned from two-week space shuttle missions and 60 percent who spent six months aboard the International Space Station were diagnosed with eye problems. Two recent investigations examined mechanisms that may explain eye changes in spaceflight, help find ways to minimize this health risk to astronauts and eventually prevent and treat eye diseases on Earth. [More]
Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Merck provides update on MK-8931 investigational oral therapy for Alzheimer’s disease

Merck, known as MSD outside the United States and Canada, today provided an update on the development program for MK-8931, a novel investigational oral β-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor. [More]

Prana completes treatment phase of IMAGINE Alzheimer’s Disease clinical trial

Prana Biotechnology, a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease clinical trial. [More]
Penn researchers identify protein that could clear Alzheimer's plaques

Penn researchers identify protein that could clear Alzheimer's plaques

The body is structured to ensure that any invading organisms have a tough time reaching the brain, an organ obviously critical to survival. Known as the blood-brain barrier, cells that line the brain and spinal cord are tightly packed, making it difficult for anything besides very small molecules to cross from the bloodstream into the central nervous system. While beneficial, this blockade also stands in the way of delivering drugs intended to treat neurological disorders, such as Alzheimer's. [More]
Bonn researchers use reprogrammed neurons for drug testing in Alzheimer patients

Bonn researchers use reprogrammed neurons for drug testing in Alzheimer patients

Why do certain Alzheimer medications work in animal models but not in clinical trials in humans? A research team from the University of Bonn and the biomedical enterprise LIFE & BRAIN GmbH has been able to show that results of established test methods with animal models and cell lines used up until now can hardly be translated to the processes in the human brain. [More]